SUNPHARMA Sun Pharmaceutical Industries Q4 FY25 results (Jan–Mar 2025) and concall
Sun Pharmaceutical Industries reported a strong Q4 and full year FY25, driven by robust performance in India and Global Specialty segments. Full year sales grew 9% to Rs. 520,412 million, with EBITDA expanding 17.3% to Rs. 152,717 million, achieving a 29% margin. Q4 sales increased 8.5% to Rs. 128,156 million, and EBITDA grew 22.4% to Rs. 37,161 million. The company proposed a total dividend of Rs. 16 per share for FY25, reflecting confidence in its financial health and future growth prospects.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|
| Revenue | 13,291 | 13,675 | 12,959 |
| EBITDA | 3,939 | 4,009 | 3,716 |
| Net profit | 3,037 | 2,913 | 2,154 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
